Axsome Therapeutics AXSM Change in AP
Change in AP at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's change in ap.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's change in AP?
- Axsome Therapeutics (AXSM) reported change in AP of $41.17M in Q1 2026.
- How has Axsome Therapeutics's change in AP changed year-over-year?
- Axsome Therapeutics's change in AP increased by 201.3% year-over-year, from $13.66M to $41.17M.
- What is the long-term trend for Axsome Therapeutics's change in AP?
- Over 2 years (2022 to 2024), Axsome Therapeutics's change in AP has grown at a 10.9% compound annual growth rate (CAGR), from $25.46M to $31.32M.
- What does change in AP mean?
- The net change in money the company owes to its suppliers.
- How do you interpret change in AP?
- An increase provides a source of cash, while a decrease represents a cash outflow to settle obligations.
- How does change in AP compare across companies?
- Standard working capital metric; companies often manage this to optimize cash conversion cycles.